Elvar Örn
Viktorsson
ab,
Reidun
Aesoy
c,
Sindre
Støa
a,
Viola
Lekve
c,
Stein Ove
Døskeland
d,
Lars
Herfindal
c and
Pål
Rongved
*a
aSchool of Pharmacy, Department of Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N0316 Oslo, Norway. E-mail: pal.rongved@farmasi.uio.no
bSchool of Health Sciences, Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, IS-107 Reykjavik, Iceland
cCentre for Pharmacy, Department of Clinical Science, University of Bergen, Jonas Lies vei 87, N-5021 Bergen, Norway
dDepartment of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5021 Bergen, Norway
First published on 19th April 2021
Novel chemotherapeutic strategies for acute myeloid leukemia (AML) treatment are called for. We have recently demonstrated that the phenazine 5,10-dioxide natural products iodinin (3) and myxin (4) exhibit potent and hypoxia-selective cell death on MOLM-13 human AML cells, and that the N-oxide functionalities are pivotal for the cytotoxic activity. Very few structure–activity relationship studies dedicated to phenazine 5,10-dioxides exist on mammalian cell lines and the present work describes our efforts regarding in vitro lead optimizations of the natural compounds iodinin (3) and myxin (4). Prodrug strategies reveal carbamate side chains to be the optimal phenol-attached group. Derivatives with no oxygen-based substituent (–OH or –OCH3) in the 6th position of the phenazine skeleton upheld potency if alkyl or carbamate side chains were attached to the phenol in position 1. 7,8-Dihalogenated- and 7,8-dimethylated analogs of 1-hydroxyphenazine 5,10-dioxide (21) displayed increased cytotoxic potency in MOLM-13 cells compared to all the other compounds studied. On the other hand, dihalogenated compounds displayed high toxicity towards the cardiomyoblast H9c2 cell line, while MOLM-13 selectivity of the 7,8-dimethylated analogs were less affected. Further, a parallel artificial membrane permeability assay (PAMPA) demonstrated the majority of the synthesized compounds to penetrate cell membranes efficiently, which corresponded to their cytotoxic potency. This work enhances the understanding of the structural characteristics essential for the activity of phenazine 5,10-dioxides, rendering them promising chemotherapeutic agents.
![]() | ||
Fig. 1 The structure of phenazine 5,10-dioxide (1), phenazine (2) with numbered positions and the natural products iodinin (3) and myxin (4). |
Iodinin (3) was one of the first phenazines to be discovered, first isolated in 1939 by Davis et al., from cultures of Brevibacterium iodinum.12,13 Its weak to moderate antimicrobial activities have been known for decades,3,14,15 and early studies by Hano et al. also showed iodinin (3) to expand the lifetime of mice with Ehrlich sarcoma relative to placebo control.16 Although evidence from in vitro experiments strongly suggest iodinin (3) to be a promising candidate to pursue in new options for AML treatment,11,17 a major drawback is the very poor solubility in aqueous solvents. This issue needed to be resolved in order to obtain a preclinical evaluation of iodinin's potential as an anticancer drug. The poor aqueous solubility stems from the two intramolecular ion–dipole bonds resulting in low solute–solvent interactions (see 3, Fig. 1). Myxin (4) was isolated from Sorangium sp. in 1966 (ref. 18) and has received attention from the medicinal chemistry community mainly because of its antimicrobial profile.3,4,19 In fact, myxin (4) was earlier marketed as a cupric complex (Unitrop®) in veterinary medicine for treatment of topical infections.20
Two modes of action have been proposed for the biological activity of myxin (4) and iodinin (3). Hollstein et al. demonstrated that both of them are capable of DNA intercalation, especially in guanine–cytosine rich regions of the DNA-double strand at concentrations similar to those required for other known intercalators like ethidium bromide and actinomycin.21,22 They also showed myxin (4) to affect the incorporation rate of CTP and GTP into RNA, but not of ATP and UTP.21 The other proposed mechanism is by generation of reactive oxygen species (ROS). Gates et al.23 showed phenazine 5,10-dioxides like myxin (4) being able to undertake a bio reductive activation to form a radical intermediate of the mother compound (Scheme 1), which further collapses to unleash the cytotoxic hydroxyl radical (˙OH).23 They found also that myxin (4) can induce cell death of human colorectal HCT-116 cells under both aerobic and anaerobic conditions.23 It is widely accepted that hydroxyl radicals cause DNA damage and are able to abstract hydrogens from the deoxyribose sugars in the DNA-double strand helix.24 This is a typical result for drugs that unleash ˙OH radicals such as tirapazamine (10, Fig. 3), as earlier demonstrated by Gates and co-workers.25
![]() | ||
Scheme 1 Discharge of the hydroxyl radical (˙OH) upon bio-reductive activation of myxin (4).23 |
We have recently published an efficient synthesis of iodinin (3), myxin (4) and several alkylated analogs, and studied their cytotoxic effects on human AML-cells (MOLM-13).26 The 1-hydroxy-6-(2-ethoxy-2-oxoethoxy) phenazine 5,10-dioxide (7) was found to be the most potent analog with ability to induce cell death, showing EC50 at sub-micromolar concentrations (see Fig. 2).
Several N-oxidized heterocyclic aromatic scaffolds have been reported to act more potently in hypoxic than normoxic environment. Examples are phenazine 5,10-dioxides (1),8,27 quinoxaline 1,4-dioxides28 (8) and 1,2,4-benzotriazine 1,4-dioxides (9).29 The latter class includes tirapazamine (3-amino-1,2,4-benzotriazine 1,4-dioxide, 10), a lead prototype of hypoxia selective prodrugs and a subject of several phase I, II and III clinical trials for treatment of various cancers.30–32 The rapid cell growth and incomplete vasculature in tumors generate a hypoxic environment33 where hypoxia selective drugs could play a role in antineoplastic treatment.34 Cimmino et al. reviewed phenazines and cancer, concluding that phenazine 5,10-dioxides have the highest potential among phenazines to be exploited for cancer therapy.5
We wanted to further exploit the anti-cancer potential of the phenazines by (i) synthesis of bio-activatable prodrugs of O-functionalized phenazine 5,10-dioxides with increased aqueous solubility, (ii) increase their potency against cancer cells by rationally optimize the ring substitution patterns, or by utilizing other related scaffolds. Further we wanted to (iii) assess cytotoxicity of the analogs on cancer cells and non-cancerous cell lines to develop a SAR study and to be able to understand why some analogs are superior leads compared to others. Taken together, in the present study we show that improvement of bioactivity as well as physico-chemical properties of simple molecules like the phenazines gives new insight in how this scaffold can be optimized for future drug development. The phenazine 5,10-dioxides require a bioreductive process to discharge an ˙OH radical and can therefore be viewed as prodrugs (Scheme 1). In this paper however, the term prodrug is specifically used for analogs with side chain functionalities attached to their phenols and are generally regarded as labile towards aqueous or enzymatic hydrolysis (esters, carbonates, carbamates). In theory, such compounds could have better physicochemical properties than the lead iodinin (3), improving factors such as solubility and membrane crossover. Once entered the cell, such prodrugs could either release their cytotoxic hydroxyl radical before or after hydrolysis of the side chain. We also aim to investigate if other non-cleavable substituents than those published earlier26 can alter the anti-AML activity of the phenazine 5,10-dioxide scaffold.
Next in line were carbamate functionalities. Attempts to react iodinin (3) with a carbamoyl chloride in PhMe with DMAP and Et3N only resulted in trace conversions (TLC analysis). Iodinin (3) showed no nucleophilicity towards any isocyanates in attempts to form primary carbamates. However, when DABCO was exposed to iodinin (3) and a neat carbamoyl chloride, the reaction mixture started to produce fume. The cherry red carbamate analogs 15–17 were thus synthesized as depicted in Scheme 2. The yields from these reactions aimed to mono-functionalize iodinin (3) were modest (9–33%). Myxin (4) was rapidly transformed into the orange-colored carbamate-analogs 18–20 using the same method in good yields (see Scheme 2). The higher yields for myxin (4) can be explained by its far superior solubility in organic media compared to iodinin (3) and the functionalization of only a single phenol group instead of two. Interestingly DABCO does not deprotonate phenols, because if such a deprotonation did occur, the reaction mixture would instantly switch color from red to dark green, like for the K2CO3/18-crown-6 system used for alkylations of iodinin (3).26 This suggests that DABCO activates the carbamoyl chloride allowing the neutral phenol moiety of the phenazine to attack the DABCO–carbamoyl chloride complex as depicted in Scheme 3.
The next step was to construct phenazine 5,10-dioxides lacking an oxygen substituent in position 6. 1-Hydroxyphenazine 5,10-dioxide (21) was synthesized by two separate strategies (see Scheme 4). First, commercially obtained 1-hydroxyphenazine (22) was oxidized to 21 using pulse-wise addition of mCPBA in toluene over a period of 5–6 hours, as reported previously for the synthesis of iodinin (3).26 This method yielded the dioxide (21) in 49% yield at a single gram scale. In an alternative approach, a Beirut reaction35 was undertaken as cyclohexane-1,2-dione and benzofuroxan (23) were condensed in neat diethylamine. This gave a filtered bright red crude that was oxidized using mCPBA. This 2-step procedure gave 2 g of isolated 1-hydroxyphenazine 5,10-dioxide (21) in 40% yield.
The reaction of 21 with ethyl bromoacetate in the presence of K2CO3 and 18-crown-6 gave compound 24 in 84% yield. This molecule was synthesized to serve as an analog to 7 (see Fig. 2), a highly cytotoxic compound in MOLM-13 cells.26 The same step, when repeated with only tert-butyl bromoacetate, produced 25, and again with 2-chloro-N,N-diethylacetamide (in addition to KI) gave 26 in 25% yield after recrystallization from hot EtOH. The main building block 21 was also exposed to carbamoyl chlorides and DABCO forming carbamate analogs 27–29 in 73–87% yields (see Scheme 4).
7,8-Disubstituted 1-methoxyphenazines 36–39 were synthesized via the classic condensation procedure using 1,2-benzoquinones and O-phenylenediamines as starting materials. Oxidation of 3-methoxycatechol (30) using ortho-chloranil in cold ether afforded the corresponding 1,2-benzoquinone 31 after filtration of the reaction mixture which was immediately transferred to an acidic toluene solution containing a corresponding ortho-phenylenediamine (32–35) (see Scheme 5). These efforts afforded 7,8-disubstituted-1-methoxyphenazines 36–39 isolated in moderate to good yields.
Similar work had been performed earlier by Cushman et al.36 and Huigens III and co-workers.1 Next, each 1-methoxyphenazine (36–39) was individually reacted in BBr3 neat under reflux to afford the corresponding 1-hydroxyphenazines 40–43 in yields 87% and higher.
The 1-hydroxyphenazines 40–43 were then exposed to a pulse-wise addition of mCPBA in toluene at 80 °C to give 7,8-disubstituted-1-hydroxyphenazine 5,10-dioxides 44–47 in non-optimized, yet acceptable yields for further use (see Scheme 5). Especially, 7,8-dibromo and 7,8-dichloro substituted analogs 45 and 46 were difficult to purify due to poor solubility and high lipophilicity resulting in tailing on the silica gel. They were thus not subjected to biological testing but the crudes after flash column chromatography could be used for further synthesis.
7,8-Disubstituted-1-hydroxyphenazine 5,10-dioxides 44–47 were subsequently functionalized with ethyl-bromoacetate (Scheme 6). These compounds were also synthesized to serve as mimics for the cytotoxic compound 7 (see Fig. 2). In addition, compounds 44–47 were also reacted with the hydrochloride salt of 4-methyl-1-piperazinecarbonyl chloride in order to give piperazine analogs 52–55 in good yields (Scheme 6). 7,8-Dimethyl-1-hydroxyphenazine 5,10-dioxide (44) was also functionalized affording the diethylamide analog 56 and the pyrrolidine carbamate 57 (Scheme 7).
The last step was the synthesis of 2-ring analogs. 2,3-Dimethylquinoxalin-5-ol (59) was prepared by reducing 3-amino-2-nitrophenol (58) with sodium dithionite refluxing in a basic mixture of MeOH/H2O (see Scheme 8). The crude mixture was concentrated to a slurry in vacuo, diluted with AcOH–PhMe (2:
3) and subsequently exposed to 2,3-diketo-butane yielding 59 in 79% yield over 2 steps. A subsequent mCPBA oxidation gave the corresponding dioxide 60 in 80% yield after flash column chromatography. Further functionalization with carbamoyl chlorides gave carbamate analogs 61 and 62 as well. Interestingly, 60 did not tolerate the presence of K2CO3/18-crown-6 system in alkylation attempts. TLC analysis revealed multiple inseparable products formed in combination with unreacted starting material. An offered explanation is that DABCO does not deprotonate the phenol functionality of 60 like the K2CO3/18-crown-6 reaction conditions.
Cpd # | EC50 (μM) MOLM-13 | EC50 (μM) NRK | EC50 (μM) H9c2 | Permeability (PAMPA) | |||
---|---|---|---|---|---|---|---|
19% O2 | 2% O2 | 19% O2 | 2% O2 | 19% O2 | P eff | Classification | |
Cell viability was assessed by the WST-1 proliferation assay and Hoechst staining 24 h after treatment of cells with various concentrations of iodinin (3) or its analogues. Non-linear regression analyses were performed using SigmaPlot in order to calculate the given EC50 values. The EC50 values of tirapazamine (10; TPZ) are based on microscopic evaluation (marked with *), whereas the EC50 values of iodinin and its analogues are based on the WST-1 results, and all are adjusted relative to untreated control cells in each experiment. The data are average of 4–6 experiments for MOLM-13 and 2–3 for NRK and H9c2 cells, ± SEM. a Poor solubility in DMSO. n.d.: not determined b Ref: Viktorsson et al.26Peff: permeability calculated as described in methods section. c Denotes that n ≥ 3. For all other samples, n = 2. Classification: ip: impermeable, pp: poor permeability, ip: intermediate permeability, p: permeable.48 | |||||||
3 (iodinin) | 2.0 ± 0.07b | 0.79 ± 0.10b | >50 | >50 | >50 | −5.64c | Intermediate |
4 (myxin) | 1.4 ± 0.30b | 0.77 ± 0.13b | 77 ± 11 | 76 ± 14 | 46 ± 4.1 | −4.94 | High |
7 | 0.57 ± 0.06b | 0.49 ± 0.12b | 12 ± 1.7 | 18 ± 1.5 | 15 ± 0.9 | −4.84c | High |
10 (TPZ) | 95 ± 8*b | 22 ± 2*b | >100* | 35 ± 6.3* | >100* | — | — |
11 | 11.0 ± 0.7 | 8.9 ± 1.71 | n.d. | n.d. | >25 | −6.06 | Low |
12 | 36 ± 0.1 | 22 ± 2.8 | n.d. | n.d. | >25 | −7.74 | Impermeable |
13 | 50 ± 0.4 | 66 ± 2.2 | n.d. | n.d. | >100 | −7.32c | Impermeable |
14 | 6.1 ± 0.05 | 4.0 ± 0.33 | >25 | >25 | >25 | −4.75 | High |
15 | 1.5 ± 0.16 | 1.4 ± 0.06 | 53 ± 2.0 | 59 ± 1.1 | 100 ± 13 | −5.96c | Low |
16 | 0.86 ± 0.05 | 0.79 ± 0.089 | 9.6 ± 0.38 | 15 ± 1.0 | 12 ± 0.7 | −4.74 | High |
17 | 0.89 ± 0.03 | 0.70 ± 0.04 | 49 ± 1.8 | 62 ± 1.3 | 64 ± 9.2 | −5.06 | High |
18 | 1.0 ± 0.06 | 0.98 ± 0.08 | 26 ± 2.1 | 39 ± 4.2 | 26 ± 0.9 | −5.74 | Low |
19 | 2.0 ± 0.11 | 1.8 ± 0.17 | 32 ± 2.5 | 35 ± 1.5 | 35 ± 3.3 | −5.1 | High |
20 | 1.9 ± 0.07 | 1.7 ± 0.09 | 22 ± 1.7 | 29 ± 0.7 | 35 ± 1.8 | −5.3 | High |
21 | 11 ± 1.8 | 12 ± 0.04 | 79 ± 4.2 | >100 | >100 | −4.74 | High |
24 | 1.5 ± 0.14 | 1.7 ± 0.29 | 26 ± 0.8 | 25 ± 0.2 | 20 ± 2.9 | −4.93 | High |
25 | 2.2 ± 0.09 | 1.9 ± 0.11 | 26 ± 0.7 | 25 ± 1.9 | 20 ± 2.1 | −4.76 | High |
26 | 1.2 ± 0.08 | 1.4 ± 0.15 | 13 ± 0.01 | 16 ± 1.0 | 23 ± 0.1 | −5.2 | High |
27 | 1.5 ± 0.18 | 1.9 ± 0.05 | 25 ± 0.2 | 37 ± 1.9 | 36 ± 11 | −4.85 | High |
28 | 1.3 ± 0.15 | 2.1 ± 0.16 | 19 ± 1.3 | 25 ± 0.6 | 16 ± 2.6 | −4.95 | High |
29 | 1.5 ± 0.18 | 1.2 ± 0.15 | 18 ± 0.6 | 21 ± 2.4 | 13 ± 0.5 | −4.91 | High |
44 | 2.8 ± 0.25 | 2.3 ± 0.10 | >50 | >50 | >50 | −5.45 | Intermediate |
45 | —a | >10a | n.d. | n.d. | n.d. | −7.23 | Impermeable |
48 | 8.3 ± 0.78 | 6.3 ± 0.25 | 140 ± 2 | >100 | >100 | −4.93 | High |
50 | 0.41 ± 0.05 | 0.38 ± 0.04 | 3.1 ± 0.02 | 4.7 ± 0.09 | 1.3 ± 0.2 | −5.16 | High |
51 | 2.4 ± 0.03 | 1.6 ± 0.09 | 10 ± 0.7 | 9.7 ± 2.40 | 3.3 ± 0.50 | −5.24 | High |
52 | 0.63 ± 0.05 | 0.54 ± 0.06 | 12 ± 1.0 | 13 ± 0.7 | 9.4 ± 0.55 | −4.97 | High |
53 | 2.8 ± 0.18 | 1.8 ± 0.10 | 2.0 ± 0.06 | 7.5 ± 0.38 | 2.3 ± 0.05 | −5.26c | High |
54 | 0.34 ± 0.04 | 0.32 ± 0.06 | 11 ± 1.0 | 15 ± 1.8 | 3.2 ± 0.10 | −4.97c | High |
55 | 0.41 ± 0.04 | 0.23 ± 0.03 | 6.2 ± 0.02 | 7.6 ± 0.60 | 2.2 ± 0.53 | −4.88 | High |
56 | 1.8 ± 0.24 | 3.4 ± 0.8 | 21 ± 0.3 | 52 ± 1.2 | 41 ± 5.7 | −5.18 | High |
57 | 1.5 ± 0.02 | 0.78 ± 0.11 | 6.6 ± 0.04 | 8.9 ± 0.06 | 8.7 ± 1.15 | −4.85 | High |
60 | >200 | >200 | n.d. | n.d. | n.d. | −4.35 | High |
61 | >200 | >200 | n.d. | n.d. | n.d. | −4.48 | High |
62 | >200 | >200 | n.d. | n.d. | n.d. | −4.65 | High |
Mono-substituted carbamate analogs of iodinin (15–17) or myxin (18–20) displayed high potency towards the MOLM-13 cells and were all equally or more potent than their respective parent compounds iodinin (3) and myxin (4) towards MOLM-13 cells (Table 1). Of iodinin carbamates 15–17, compound 15 had lowest potency, which corresponds with it having lower permeability compared to compounds 16 and 17. This is likely due to the tertiary amine of N-methyl piperazine becoming positively charged at physiological pH (compounds 15 and 18) and therefore reducing the ability for membrane crossover. Myxin carbamate analogs 19 and 20 resided within the high permeability group. Although the piperazine analogs 15 and 18 displayed low permeability according to PAMPA results, they were both highly cytotoxic towards the MOLM-13 cell line. None of the iodinin or myxin carbamates (15–20) appeared to be more cytotoxic under hypoxic conditions (2% O2, Table 1). The lack of hypoxia selectivity for 15–20 might be caused by an electron withdrawing effect of the carbamate group making the aromatic phenazine system less electron rich. In comparison, a phenazine like myxin (4) shows greater hypoxia selectivity where the phenol- and the methoxy-functionalities contribute to a higher electron density in the aromatic ring system. To reflect on that note, SAR-studies conducted on tirapazamine (10) showed weakly electron donating groups to be more likely affording a higher hypoxic cytotoxicity ratio.29 When tested against the NRK- and H9c2 cells, the carbamates (15–20) showed EC50 values about 15–80 times higher than for the AML cells (Table 1). In short conclusion, carbamates of iodinin and myxin represent an attractive new class of anti-AML therapeutic agents with an attractive therapeutic index like the lead compound myxin (3).
In conclusion, compounds 24–29 exhibited poorer selectivity between AML-cells and non-cancerous cell lines compared to monosubstituted carbamates of both iodinin and myxin (compounds 15–20).
Four new analogs turned out to be particularly potent in MOLM-13 cells; the 7,8-dimethyl and 7,8-dihalogen-piperazine analogs 52, 54 and 55 and the 7,8-dichloro analog 50 bearing the 2-ethoxy-2-oxoethoxy side chain (see Table 1). The 7,8-dichloropiperazine analog 54 was found to be more selective towards leukemic cell lines compared with NRK-cells by a factor of more than 30 at 19% O2 and a factor of 45 in a hypoxic setting. The 7,8-dichloro-analog 54 and the 7,8-dibromo-analog 55 were the most potent of all the compounds tested against MOLM-13 cells, both at high and low oxygen levels. In agreement with their toxicity, these compounds were all highly permeable in the PAMPA assay (Table 1). However, in addition to the increased efficacy towards AML cells, the H9c2 cardiomyoblast cell line was also more responsive to the dihalogenated compounds 50, 51, 54 and 55, particularly compared to the NRK epithelial cell line. This indicates that the dihalogenated compounds 50, 51, 54 and 55 may not be suitable as lead compounds in AML therapy due to potential adverse effects on heart tissue.
The 7,8-dimethyl piperazine analog 52 had high potency towards AML cells, and was also found to be less toxic towards the non-cancerous cell lines compared to the halogenated compounds 50, 54 and 55 (Table 1). The 7,8-dimethyl pyrrolidine carbamate 57 showed comparable activity in MOLM-13 to that of myxin (4) and relatively good hypoxia selectivity was observed, but it was more toxic to NRK cells than iodinin (3) and myxin (4). As mentioned earlier, the iodinin-pyrrolidine analog 16 was also found to be more toxic than the iodinin carbamates 15 and 17. This could indicate that a pyrrolidine-carbamate based side-chain is unsuited for further development of a phenazine 5,10-dioxide anti-AML agents. The 7,8-dimethyl analogs 56 and 48 differ in their side chain (ethyl ester vs. diethyl amide) and the diethylamide 56 was more potent than the ethyl ester 48 towards the AML cell line MOLM-13 (Table 1). Both these analogs were less toxic in NRK and H9c2 compared to their 1-hydroxyphenazine 5,10-dioxide analogs 26 and 24.
Finally, a series of bicyclic aromatic N-oxides with carbamate side chains were evaluated (60–62). Despite their two N-oxides and their high membrane permeability (Table 1), we did not detect any cytotoxic activity towards the AML cell line MOLM-13 (EC50 > 200 μM, Table 1), indicating that three-cyclic aromatic rings are important for the cytotoxic activity.
In correlation to carbamate metabolism in vivo, the anticancer drug irinotecan is an FDA approved carbamate prodrug which is biodegraded to the active camptothecin phenol-analog SN-38 by human liver microsomal carboxylesterases.46,47 Thus, whether the carbamates presented in this work (such as 15–20etc.) are hydrolyzed and cleaved from its parent 1-hydroxyphenazine 5,10-dioxide analog by intracellular enzymes prior to cell death is not yet established. We can therefore not exclude the possibility that the analogs themselves can generate a higher toxicity by e.g. generate ROS or facilitate DNA-intercalation prior to hydrolysis of the carbamate functional group.
To identify molecular structures which could be determinant for the desired anti-AML activity, we performed a Kernel-based partial least square regression (see ESI† document 2 for details on methods and results). The KPLS model showed that –OH substituents in position 1 and 6 of the analogs were associated with high activity towards AML cells, but not NRK cells. This suggests that analogs should be mono-substituted with an –OR group in order to retain AML selectivity, but this is probably not the case if the analogs are prodrugs where cleavage of the linker from the phenazine parent compound will result in an –OH group. The nature of the linker was also important for activity. In general, carbamate-linkers were associated with high activity, whereas carbonate-linkers related to low activity. Taken together, these data could be used to further optimize analogs of the phenazine 5,10-dioxide scaffold to develop highly active and selective compounds against AML.
We conclude that both iodinin and myxin carbamate prodrugs (15–20) and the 7,8-dimethyl analog 52 meet criteria to be investigated further as leads in terms of antileukemic activities, displaying both high potency and cell selectivity towards the MOLM-13 cell line. Published SAR studies on phenazine 5,10-dioxides are scarce in literature, but utilization of in silico KPLS models showed that the oxygen substituent in position 1 and 6 was involved in the AML selectivity observed for the analogs. Moreover, it also supported our findings that introduction of a fourth ring to create a tetracyclic structure shifted the activity to general cytotoxic, without preferences towards AML cells. We believe the synthetic methods and biological trends derived from the present work could pave the way, not only for enhanced research on phenazine 5,10-dioxides, but also to afford novel drug candidates for the treatment of AML with less side-effects than current standards in AML induction chemotherapy can offer.
All analogs were dissolved in DMSO (D5879, Sigma-Aldrich) at concentrations between 2.5 and 20 mM before testing. For cytotoxic testing, the MOLM-13 cells were seeded as 20000 cells/well, while NRK and H9c2 cells were seeded as 5
000 cells/well in 96-well Microplates (#167008, Thermo Scientific™ Nunc™ MicroWell™) with 100 μL medium/well. The MOLM-13 cells were seeded at the day of the experiment, while the NRK and H9c2 cells were seeded the day before the experiment, to allow them to attach to the surface of the wells before adding compounds. The cells were exposed to various concentrations of iodinin or its analogs for 24 h before the cell proliferation reagent WST-1 was used to assess the viability, in accordance with the manufacturer's instructions (11644807001, Roche Diagnostics, Sigma-Aldrich). The cells were next fixed in 2% buffered formaldehyde (pH 7.4) with the DNA-specific dye Hoechst 33342 (Polysciences Inc.) and assessed for cell death by UV-microscopy based on nuclear morphology.49 The highest concentration of analog corresponded to 1% of DMSO, which alone gave less than 7% cell death as judged by nuclear morphology.
EC50 values were determined by analyses of WST-1 signal results as well as microscopic evaluation of cell death by four-parameter regression analyses using the SigmaPlot software (Systat Software Inc. San Jose, CA):
Membrane permeability were classified by the range defined by Bennion et al., allowing us to divide the compounds into four groups, compounds with high permeability (logPeff > −5.33), intermediate permeability (log
Peff > −5.66 and <−5.33), low permeability (log
Peff > −6.14 and <−5.66) impermeable (log
Peff < −6.14).
Footnote |
† Electronic supplementary information (ESI) available: Synthetic procedures, characterization data, NMR spectra, detailed results from PAMPA assay, KPLS-data. See DOI: 10.1039/d1md00020a |
This journal is © The Royal Society of Chemistry 2021 |